Very proud of my co-founders Dr. Janine Sengstack and Dr. Hao Li in publishing their work, originally started in 2017: Sengstack et al, Systematic identification of single transcription factor perturbations that drive cellular and tissue rejuvenation, PNAS, 2026
This is the first research to demonstrate repression of a single transcription factor (TF) can reverse cell aging.
This matters because single-target repression enables siRNA as a modality, significantly improving therapeutic translatability for cell reprogramming with once every 6-12 month dosing, tissue-specificity, low manufacturing costs and a demonstrated safety profile.
Imagine in 2040 you can receive a once-per-year at home injection with a cocktail of siRNA medicines to restore gene networks by targeting TFs in each major tissue.
At Junevity, we built the RESET Platform to identify TF targets for tissue-specific repression with siRNA to treat complex and age-related diseases. We look forward to bringing our first therapeutics to human clinical trials as soon as possible.